Pacira BioSciences Files Proxy Statement

Ticker: PCRX · Form: DEFA14A · Filed: Mar 14, 2025 · CIK: 1396814

Pacira Biosciences, Inc. DEFA14A Filing Summary
FieldDetail
CompanyPacira Biosciences, Inc. (PCRX)
Form TypeDEFA14A
Filed DateMar 14, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, regulatory-filing, corporate-governance

TL;DR

Pacira BioSciences filed its proxy statement, no fee needed. Get ready for shareholder votes.

AI Summary

Pacira BioSciences, Inc. filed a Definitive Proxy Statement (DEFA14A) on March 14, 2025, related to soliciting materials under Section 240.14a-12. The filing indicates no fee was required for this submission. The company, previously known as Pacira Pharmaceuticals, Inc., is headquartered in Brisbane, California.

Why It Matters

This filing is a routine proxy statement, indicating the company is preparing for shareholder meetings or votes, which could involve important corporate decisions.

Risk Assessment

Risk Level: low — This is a standard regulatory filing (DEFA14A) and does not inherently present new risks to investors.

Key Players & Entities

  • Pacira BioSciences, Inc. (company) — Registrant
  • 0001396814 (company) — Central Index Key
  • 2000 Sierra Point Parkway, Suite 900, Brisbane, CA 94005 (company) — Business Address
  • Pacira Pharmaceuticals, Inc. (company) — Former Company Name
  • 20101029 (date) — Date of Name Change

FAQ

What is the purpose of a DEFA14A filing?

A DEFA14A filing is a Definitive Proxy Statement filed with the SEC, used by companies to solicit proxies from shareholders for an upcoming meeting or vote.

When was this specific DEFA14A filed?

This DEFA14A filing was filed on March 14, 2025.

Does this filing require a fee?

No, the filing explicitly states 'No fee required.'

What is Pacira BioSciences, Inc.'s primary business classification?

Pacira BioSciences, Inc. is classified under Standard Industrial Classification (SIC) code 2834, which is 'Pharmaceutical Preparations'.

Has Pacira BioSciences, Inc. always been known by this name?

No, the company has had previous names, including Pacira Pharmaceuticals, Inc., PACIRA INC, and Blue Acquisition Corp, with the most recent name change from Pacira Pharmaceuticals, Inc. occurring on October 29, 2010.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 14, 2025 regarding Pacira BioSciences, Inc. (PCRX).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.